These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33797862)

  • 1. Calcineurin inhibitors nephrotoxicity revisited.
    Pallet N
    Am J Transplant; 2021 Sep; 21(9):2929-2930. PubMed ID: 33797862
    [No Abstract]   [Full Text] [Related]  

  • 2. Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.
    3C Study Collaborative Group
    Am J Transplant; 2018 Jun; 18(6):1424-1434. PubMed ID: 29226570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcineurin inhibitors and nephrotoxicity in children.
    Liu F; Mao JH
    World J Pediatr; 2018 Apr; 14(2):121-126. PubMed ID: 29532435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis.
    Xia T; Zhu S; Wen Y; Gao S; Li M; Tao X; Zhang F; Chen W
    Drug Des Devel Ther; 2018; 12():417-428. PubMed ID: 29535503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcineurin Inhibitors Nephrotoxicity Prevention Strategies With Stress on Belatacept-Based Rescue Immunotherapy: A Review of the Current Evidence.
    El Hennawy HM; Faifi ASA; El Nazer W; Mahedy A; Kamal A; Al Faifi IS; Abdulmalik H; Safar O; Zaitoun MF; Fahmy AE
    Transplant Proc; 2021 Jun; 53(5):1532-1540. PubMed ID: 34020797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety of calcineurin inhibitors for kidney-transplant patients.
    Malvezzi P; Rostaing L
    Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limitations of current liver transplant immunosuppressive regimens: renal considerations.
    Zhang W; Fung J
    Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):27-32. PubMed ID: 28119255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion to Everolimus in Kidney Transplant Recipients With Calcineurin Inhibitor-Induced Nephropathy: 3 Case Reports.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Transplant Proc; 2019 Jun; 51(5):1424-1427. PubMed ID: 31060742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy.
    Pilmore HL; Dittmer ID
    Clin Transplant; 2002 Jun; 16(3):191-5. PubMed ID: 12010142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
    Camilleri B; Bridson JM; Halawa A
    Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioenergetic maladaptation and release of HMGB1 in calcineurin inhibitor-mediated nephrotoxicity.
    Zmijewska AA; Zmijewski JW; Becker EJ; Benavides GA; Darley-Usmar V; Mannon RB
    Am J Transplant; 2021 Sep; 21(9):2964-2977. PubMed ID: 33724664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study on renal biopsy before and after long-term calcineurin inhibitors therapy: an insight for pathogenesis of its toxicity.
    Singh L; Singh G; Sharma A; Sinha A; Bagga A; Dinda AK
    Hum Pathol; 2015 Jan; 46(1):34-9. PubMed ID: 25449629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
    Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension.
    Hošková L; Málek I; Kopkan L; Kautzner J
    Physiol Res; 2017 May; 66(2):167-180. PubMed ID: 27982677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.
    Jacobson PA; Schladt D; Israni A; Oetting WS; Lin YC; Leduc R; Guan W; Lamba V; Matas AJ;
    Transplantation; 2012 Mar; 93(6):624-31. PubMed ID: 22334041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic calcineurin inhibitor nephrotoxicity-lest we forget.
    Chapman JR
    Am J Transplant; 2011 Apr; 11(4):693-7. PubMed ID: 21446974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.